메뉴 건너뛰기




Volumn 100, Issue 1, 2014, Pages 100-106

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

(13)  Dimopoulos, Meletios A a   Orlowski, Robert Z b   Facon, Thierry c   Sonneveld, Pieter d   Anderson, Kenneth C e   Beksac, Meral f   Benboubker, Lotfi g   Roddie, Huw h   Potamianou, Anna i   Couturier, Catherine j   Ataman, Ozlem k,l   Van De Velde, Helgi m   Richardson, Paul G e  


Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

EID: 84920168620     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.112037     Document Type: Article
Times cited : (28)

References (43)
  • 2
    • 35148825003 scopus 로고    scopus 로고
    • Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-toevent results of the APEX trial
    • Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-toevent results of the APEX trial. Blood. 2007; 110(10):3557-60.
    • (2007) Blood , vol.110 , Issue.10 , pp. 3557-3560
    • Richardson, P.G.1    Sonneveld, P.2    Schuster, M.3    Irwin, D.4    Stadtmauer, E.5    Facon, T.6
  • 3
    • 34548539381 scopus 로고    scopus 로고
    • Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression
    • Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-901.
    • (2007) J Clin Oncol , vol.25 , Issue.25 , pp. 3892-3901
    • Orlowski, R.Z.1    Nagler, A.2    Sonneveld, P.3    Blade, J.4    Hajek, R.5    Spencer, A.6
  • 4
    • 84868096248 scopus 로고    scopus 로고
    • Updated survival analysis of a randomrandomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    • Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, et al. Updated survival analysis of a randomrandomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925-8.
    • (2012) Haematologica , vol.97 , Issue.12 , pp. 1925-1928
    • Arnulf, B.1    Pylypenko, H.2    Grosicki, S.3    Karamanesht, I.4    Leleu, X.5    Van De Velde, H.6
  • 6
    • 33745801771 scopus 로고    scopus 로고
    • Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    • Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006; 91(7):929-34.
    • (2006) Haematologica , vol.91 , Issue.7 , pp. 929-934
    • Jagannath, S.1    Richardson, P.G.2    Barlogie, B.3    Berenson, J.R.4    Singhal, S.5    Irwin, D.6
  • 7
    • 54849413402 scopus 로고    scopus 로고
    • Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
    • Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143(4):537-40.
    • (2008) Br J Haematol , vol.143 , Issue.4 , pp. 537-540
    • Jagannath, S.1    Barlogie, B.2    Berenson, J.R.3    Siegel, D.S.4    Irwin, D.5    Richardson, P.G.6
  • 8
    • 58149086029 scopus 로고    scopus 로고
    • High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: Results of a global phase 3b expanded access program
    • Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009; 144(2):169-75.
    • (2009) Br J Haematol , vol.144 , Issue.2 , pp. 169-175
    • Mikhael, J.R.1    Belch, A.R.2    Prince, H.M.3    Lucio, M.N.4    Maiolino, A.5    Corso, A.6
  • 9
    • 79955461011 scopus 로고    scopus 로고
    • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study
    • Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-40.
    • (2011) Lancet Oncol , vol.12 , Issue.5 , pp. 431-440
    • Moreau, P.1    Pylypenko, H.2    Grosicki, S.3    Karamanesht, I.4    Leleu, X.5    Grishunina, M.6
  • 11
    • 33644844108 scopus 로고    scopus 로고
    • Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial
    • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;106(6):1316-9.
    • (2006) Cancer , vol.106 , Issue.6 , pp. 1316-1319
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3    Singhal, S.4    Jagannath, S.5    Irwin, D.H.6
  • 12
    • 84885367423 scopus 로고    scopus 로고
    • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    • Moreau P, San Miguel JF, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi133-7.
    • (2013) Ann Oncol , vol.24 , pp. 133-137
    • Moreau, P.1    San Miguel, J.F.2    Ludwig, H.3    Schouten, H.4    Mohty, M.5    Dimopoulos, M.6
  • 14
    • 84881016175 scopus 로고    scopus 로고
    • Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
    • Dimopoulos MA, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, et al. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica. 2013;98(8):1264-72.
    • (2013) Haematologica , vol.98 , Issue.8 , pp. 1264-1272
    • Dimopoulos, M.A.1    Beksac, M.2    Benboubker, L.3    Roddie, H.4    Allietta, N.5    Broer, E.6
  • 15
    • 84920126185 scopus 로고    scopus 로고
    • Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (the BoMeR trial) significantly improves response and time to progression: A matched analysis of BoMeR vs APEX
    • Abstract
    • Harrison S, Quach H, Link E, Feng H, Dean J, Copeman M, et al. Bortezomib and dexamethasone from cycle 1 as treatment and maintenance for multiple myeloma relapse (the BoMeR trial) significantly improves response and time to progression: a matched analysis of BoMeR vs APEX. Haematologica. 2011;96(S1): Abstract P-236.
    • (2011) Haematologica , vol.96 , Issue.S1 , pp. 236
    • Harrison, S.1    Quach, H.2    Link, E.3    Feng, H.4    Dean, J.5    Copeman, M.6
  • 17
    • 18244428600 scopus 로고    scopus 로고
    • Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant
    • Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5): 1115-23.
    • (1998) Br J Haematol , vol.102 , Issue.5 , pp. 1115-1123
    • Blade, J.1    Samson, D.2    Reece, D.3    Apperley, J.4    Bjorkstrand, B.5    Gahrton, G.6
  • 18
    • 33846842327 scopus 로고    scopus 로고
    • A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study
    • Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007;26(4):734-53.
    • (2007) Stat Med , vol.26 , Issue.4 , pp. 734-753
    • Austin, P.C.1    Grootendorst, P.2    Anderson, G.M.3
  • 19
    • 44649173785 scopus 로고    scopus 로고
    • A critical appraisal of propensity- score matching in the medical literature between 1996 and 2003
    • Austin PC. A critical appraisal of propensity- score matching in the medical literature between 1996 and 2003. Stat Med. 2008; 27(12):2037-49.
    • (2008) Stat Med , vol.27 , Issue.12 , pp. 2037-2049
    • Austin, P.C.1
  • 20
    • 79951791644 scopus 로고    scopus 로고
    • A tutorial and case study in propensity score analysis: An application to estimating the effect of in-hospital smoking cessation counseling on mortality
    • Austin PC. A tutorial and case study in propensity score analysis: an application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res. 2011;46(1):119-51.
    • (2011) Multivariate Behav Res , vol.46 , Issue.1 , pp. 119-151
    • Austin, P.C.1
  • 21
    • 79955936633 scopus 로고    scopus 로고
    • Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): Examining whether different variables govern different time segments of survival
    • Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol. 2011;90(4):423-8.
    • (2011) Ann Hematol , vol.90 , Issue.4 , pp. 423-428
    • Barlogie, B.1    Bolejack, V.2    Schell, M.3    Crowley, J.4
  • 22
    • 84878468191 scopus 로고    scopus 로고
    • Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials
    • Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6): 980-7.
    • (2013) Haematologica , vol.98 , Issue.6 , pp. 980-987
    • Bringhen, S.1    Mateos, M.V.2    Zweegman, S.3    Larocca, A.4    Falcone, A.P.5    Oriol, A.6
  • 23
    • 84873904996 scopus 로고    scopus 로고
    • Extramedullary plasmacytoma in the presence of multiple myeloma: Clinical correlates and prognostic relevance
    • Chen HF, Wu TQ, Li ZY, Shen HS, Tang JQ, Fu WJ, et al. Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance. Onco Targets Ther. 2012;5329-34.
    • (2012) Onco Targets Ther , pp. 5329-5334
    • Chen, H.F.1    Wu, T.Q.2    Li, Z.Y.3    Shen, H.S.4    Tang, J.Q.5    Fu, W.J.6
  • 25
    • 19944428373 scopus 로고    scopus 로고
    • An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
    • Hus I, Dmoszynska A, Manko J, Hus M, Jawniak D, Soroka-Wojtaszko M, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer. 2004;91(11):1873-9.
    • (2004) Br J Cancer , vol.91 , Issue.11 , pp. 1873-1879
    • Hus, I.1    Dmoszynska, A.2    Manko, J.3    Hus, M.4    Jawniak, D.5    Soroka-Wojtaszko, M.6
  • 26
    • 0030053770 scopus 로고    scopus 로고
    • Prognostic factors in multiple myeloma: Selection using Cox's proportional hazard model
    • Pasqualetti P, Collacciani A, Maccarone C, Casale R. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model. Biomed Pharmacother. 1996;50(1):29-35.
    • (1996) Biomed Pharmacother , vol.50 , Issue.1 , pp. 29-35
    • Pasqualetti, P.1    Collacciani, A.2    Maccarone, C.3    Casale, R.4
  • 27
    • 57949103908 scopus 로고    scopus 로고
    • Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count
    • Perosa F, Minoia C, Favoino E, Prete M, Dammacco F. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. Blood Cells Mol Dis. 2009;42(1):71-6.
    • (2009) Blood Cells Mol Dis , vol.42 , Issue.1 , pp. 71-76
    • Perosa, F.1    Minoia, C.2    Favoino, E.3    Prete, M.4    Dammacco, F.5
  • 28
    • 0035196437 scopus 로고    scopus 로고
    • Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
    • Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol. 2001; 68(4):269-75.
    • (2001) Am J Hematol , vol.68 , Issue.4 , pp. 269-275
    • Rajkumar, S.V.1    Fonseca, R.2    Dispenzieri, A.3    Lacy, M.Q.4    Lust, J.A.5    Witzig, T.E.6
  • 29
    • 27644476353 scopus 로고    scopus 로고
    • Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    • Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005; 106(9):2977-81.
    • (2005) Blood , vol.106 , Issue.9 , pp. 2977-2981
    • Richardson, P.G.1    Barlogie, B.2    Berenson, J.3    Singhal, S.4    Jagannath, S.5    Irwin, D.6
  • 30
    • 77951882321 scopus 로고    scopus 로고
    • Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients
    • Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21 (2):325-30.
    • (2010) Ann Oncol , vol.21 , Issue.2 , pp. 325-330
    • Varettoni, M.1    Corso, A.2    Pica, G.3    Mangiacavalli, S.4    Pascutto, C.5    Lazzarino, M.6
  • 31
    • 14744278225 scopus 로고    scopus 로고
    • Bortezomib in combination with dexamethasone for relapsed multiple myeloma
    • Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res. 2005;29(5):587-90.
    • (2005) Leuk Res , vol.29 , Issue.5 , pp. 587-590
    • Kropff, M.H.1    Bisping, G.2    Wenning, D.3    Volpert, S.4    Tchinda, J.5    Berdel, W.E.6
  • 32
    • 78549269073 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: The collaborative study at six institutes in Kyoto and Osaka
    • Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, et al. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol. 2010;92(4):579-86.
    • (2010) Int J Hematol , vol.92 , Issue.4 , pp. 579-586
    • Kobayashi, T.1    Kuroda, J.2    Shimura, K.3    Akaogi, T.4    Kawata, E.5    Kiyota, M.6
  • 33
    • 70349971700 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived
    • Corso A, Varettoni M, Mangiacavalli S, Zappasodi P, Pica GM, Algarotti A, et al. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. Eur J Haematol. 2009;83(5):449-54.
    • (2009) Eur J Haematol , vol.83 , Issue.5 , pp. 449-454
    • Corso, A.1    Varettoni, M.2    Mangiacavalli, S.3    Zappasodi, P.4    Pica, G.M.5    Algarotti, A.6
  • 34
    • 84891855990 scopus 로고    scopus 로고
    • Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: Analysis of long-term clinical outcomes
    • Pantani L, Zamagni E, Zannetti BA, Pezzi A, Tacchetti P, Brioli A, et al. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. Ann Hematol. 2013;93(1):123-8.
    • (2013) Ann Hematol , vol.93 , Issue.1 , pp. 123-128
    • Pantani, L.1    Zamagni, E.2    Zannetti, B.A.3    Pezzi, A.4    Tacchetti, P.5    Brioli, A.6
  • 35
    • 84920131142 scopus 로고    scopus 로고
    • Efficacy of bortezomib plus dexamethasone versus bortezomib monotherapy in patients (pts) with relapsed/refractory multiple myeloma (MM): Interim results from an international electronic observational study
    • Abstract
    • Dimopoulos MA, De Samblanx H, Roussou M, Zervas K, Katodritou E, Sargin D, et al. Efficacy of bortezomib plus dexamethasone versus bortezomib monotherapy in patients (pts) with relapsed/refractory multiple myeloma (MM): interim results from an international electronic observational study. Haematologica. 2011;96 (S78):Abstract P-166.
    • (2011) Haematologica , vol.96 , Issue.S78 , pp. 166
    • Dimopoulos, M.A.1    De Samblanx, H.2    Roussou, M.3    Zervas, K.4    Katodritou, E.5    Sargin, D.6
  • 37
    • 34347365315 scopus 로고    scopus 로고
    • Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland
    • Freimann H, Calderoni A, Cornu P, Olie R. Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly. 2007;137(21-22):317-22.
    • (2007) Swiss Med Wkly , vol.137 , Issue.21-22 , pp. 317-322
    • Freimann, H.1    Calderoni, A.2    Cornu, P.3    Olie, R.4
  • 38
    • 84884703399 scopus 로고    scopus 로고
    • Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study
    • Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013; 14(11):1129-40.
    • (2013) Lancet Oncol , vol.14 , Issue.11 , pp. 1129-1140
    • Dimopoulos, M.1    Siegel, D.S.2    Lonial, S.3    Qi, J.4    Hajek, R.5    Facon, T.6
  • 39
    • 0035300479 scopus 로고    scopus 로고
    • The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
    • Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7):3071-6.
    • (2001) Cancer Res , vol.61 , Issue.7 , pp. 3071-3076
    • Hideshima, T.1    Richardson, P.2    Chauhan, D.3    Palombella, V.J.4    Elliott, P.J.5    Adams, J.6
  • 40
    • 35348898377 scopus 로고    scopus 로고
    • Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: Efficacy and clinical implications of tumor response kinetics
    • Rosinol L, Oriol A, Mateos MV, Sureda A, Garcia-Sanchez P, Gutierrez N, et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol. 2007;25(28):4452-8.
    • (2007) J Clin Oncol , vol.25 , Issue.28 , pp. 4452-4458
    • Rosinol, L.1    Oriol, A.2    Mateos, M.V.3    Sureda, A.4    Garcia-Sanchez, P.5    Gutierrez, N.6
  • 41
    • 84920165636 scopus 로고    scopus 로고
    • ® (bortezomib). Summary of product characteristics (up-dated February 2014). Available from
    • ® (bortezomib). Summary of product characteristics (up-dated February 2014). Available from: http://www.ema.europa.eu/ema/index.jsp ?curl=pages/medicines/human/medicines/ 000539/human_med_001130.jsp&mi d=WC0b01ac058001d124.
  • 42
    • 84920158156 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple Myeloma. Latest version published online is now V2. 2015. Available from
    • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Multiple Myeloma. Latest version published online is now V2. 2015. Available from: http://www.nccn.org/professionals/ physician_gls/pdf/myeloma.pdf
  • 43
    • 79952720734 scopus 로고    scopus 로고
    • Treatment options for relapsed and refractory multiple myeloma
    • Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res. 2011;17(6):1264-77.
    • (2011) Clin Cancer Res , vol.17 , Issue.6 , pp. 1264-1277
    • Lonial, S.1    Mitsiades, C.S.2    Richardson, P.G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.